Ketamine as a promising prototype for a new generation of rapid-acting antidepressants

Annals of the New York Academy of Sciences

Volumn 1344, Issue 1, 2015, Pages 66-77

  Abdallah, Chadi G ^a,b   Averill, Lynnette A ^a,b   Krystal, John H ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressant; Depression; Ketamine; Neurobiology; Treatment mechanisms

Indexed keywords

BIOLOGICAL MARKER; KETAMINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; COGNITION; CONTROLLED CLINICAL TRIAL (TOPIC); CYSTITIS; DEPRESSION; DIZZINESS; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; ELEVATED BLOOD PRESSURE; EUPHORIA; HUMAN; MENTAL DISSOCIATION; NAUSEA; NEUROBIOLOGY; PERCEPTION DISORDER; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; ANIMAL; BLOOD; METABOLISM; PATHOPHYSIOLOGY; WOUNDS AND INJURIES;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOMARKERS; DEPRESSION; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; KETAMINE; WOUNDS AND INJURIES;

EID: 84927611847     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12718     Document Type: Article

References (89)

1. Collins, P.Y. et al. 2011. Grand challenges in global mental health. Nature 475: 27-30.
2. Kessler, R.C. et al. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105.
3. Rush, A.J. et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163: 1905-1917.
4. Katz, M.M. et al. 2004. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 29: 566-579.
5. Gaynes, B.N. et al. 2009. What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatric Serv. (Washington, D.C.). 60: 1439-1445.
6. Mion, G., & T. Villevieille . 2013. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci. Therapeut. 19: 370-380.
7. Skolnick, P. et al. 1996. Adaptation of N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29: 23-26.
8. Trullas, R. & P. Skolnick . 1990. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 185: 1-10.
9. Berman, R.M. et al. 2000. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 47: 351-354.
10. Zarate, C.A., Jr. et al. 2006. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63: 856-864.
11. Murrough, J.W. et al. 2013. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am. J. Psychiatry 170: 1134-1142.
12. Niciu, M.J. et al. 2014. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Ann. Rev. Pharmacol. Toxicol. 54: 119-139.
13. Abdallah, C.G. et al. 2014. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Ann. Rev. Med. 66: 509-523.
14. Diazgranados, N. et al. 2010. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67: 793-802.
15. Ibrahim, L. et al. 2011. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 35: 1155-1159.
16. Ionescu, D.F. et al. 2014. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J. Clin. Psychiatry 75: e932-e938.
17. Ionescu, D.F. et al. 2014. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression. Bipolar Disorders. doi: 10.1111/bdi.12277.
18. Price, R.B. et al. 2009. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 66: 522-526.
19. DiazGranados, N. et al. 2010. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J. Clin. Psychiatry 71: 1605-1611.
20. Ballard, E.D. et al. 2014. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J. Psychiatr. Res. 58: 161-166.
21. Aan Het Rot, M. et al. 2012. Ketamine for depression: where do we go from here? Biol. Psychiatry 72: 537-547.
22. Murrough, J.W. et al. 2013. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol. Psychiatry 74: 250-256.
23. Lapidus, K.A. et al. 2014. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol. Psychiatry 76: 970-976.
24. Caddy, C. et al. 2014. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Therapeut. Adv. Psychopharmacol. 4: 75-99.
25. Fond, G. et al. 2014. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology 231: 3663-3676.
26. McGirr, A. et al. 2014. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol. Med. e1-e12.
27. D'Andrea, D. & R. Andrew Sewell . 2013. Transient resolution of treatment-resistant posttraumatic stress disorder following ketamine infusion. Biol Psychiatry 74: e13-14.
28. Kishimoto, A. et al. 2012. Ifenprodil for the treatment of flashbacks in female posttraumatic stress disorder patients with a history of childhood sexual abuse. Biol Psychiatry 71: e7-e8.
29. Zeng, M.C. et al. 2013. Acute stress symptoms do not worsen in posttraumatic stress disorder and abuse with a single subanesthetic dose of ketamine. Biol Psychiatry 73: e37-e38.
30. Feder, A. et al. 2014. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a Randomized Clinical Trial. JAMA Psychiatry 71: 681-688.
31. Herrera-Guzman, I. et al. 2010. Major depressive disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with major depressive disorder in recovery. J. Affective Disorders 123: 341-350.
32. Baune, B. et al. 2010. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 176: 183-189.
33. Simon, G.E. et al. 2000. Recovery from depression, work productivity, and health care costs among primary care patients. Gen. Hospital Psychiatry 22: 153-162.
34. Zajecka, J.M. 2003. Treating depression to remission. J. Clin. Psychiatry 64: 7-12.
35. Bora, E. et al. 2013. Cognitive impairment in euthymic major depressive disorder: a meta-analysis. Psychol. Med. 43: 2017-2026.
36. Hasselbalch, B.J., U. Knorr & L.V. Kessing . 2011. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J. Affective Disorders 134: 20-31.
37. Hasselbalch, B.J. et al. 2012. Cognitive deficits in the remitted state of unipolar depressive disorder. Neuropsychology 26: 642-651.
38. Li, N. et al. 2010. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
39. Moghaddam, B. et al. 1997. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 17: 2921-2927.
40. Duman, R.S. & B. Voleti . 2012. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 35: 47-56.
41. Anand, A. et al. 2000. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiatry 57: 270-276.
42. Deakin, J.F. et al. 2008. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch. Gen. Psychiatry 65: 154-164.
43. Homayoun, H. & B. Moghaddam . 2007. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27: 11496-11500.
44. Krystal, J.H. et al. 2005. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 179: 303-309.
45. Murrough, J.W. et al. 2014. Neurocognitive Effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a Randomized Controlled Trial. Neuropsychopharmacology. doi:10.1038/npp.2014.298.
46. Permoda-Osip, A. et al. 2014. Single ketamine infusion and neurocognitive performance in bipolar depression. Pharmacopsychiatry. doi: 10.1055/s-0034-1394399.
47. Shahani, R. et al. 2007. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology 69: 810-812.
48. Blier, P., D. Zigman & J. Blier . 2012. On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol. Psychiatry 72: e11-e12.
49. Szymkowicz, S.M., N. Finnegan & R.M. Dale . 2013. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J. Affective Disorders 147: 416-420.
50. Diamond, P.R. et al. 2014. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol. 28: 536-544.
51. Rasmussen, K.G. et al. 2013. Serial infusions of low-dose ketamine for major depression. J. Psychopharmacol. 27: 444-450.
52. Shiroma, P.R. et al. 2014. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J. Affective Disorders 155: 123-129.
53. Segmiller, F. et al. 2013. Repeated S-ketamine infusions in therapy resistant depression: a case series. J. Clin. Pharmacol. 53: 996-998.
54. Larkin, G.L. & A.L. Beautrais . 2011. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int. J. Neuropsychopharmacol. 14: 1127-1131.
55. Chilukuri, H. et al. 2014. Acute antidepressant effects of intramuscular versus intravenous ketamine. Ind. J. Psychol. Med. 36: 71-76.
56. Duman, R.S. & G.K. Aghajanian . 2012. Synaptic dysfunction in depression: potential therapeutic targets. Science 338: 68-72.
57. Popoli, M. et al. 2012. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat. Rev. Neurosci. 13: 22-37.
58. Kang, H.J. et al. 2012. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. Nat. Med. 18: 1413-1417.
59. Bessa, J.M. et al. 2009. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling. Mol. Psychiatry 14: 764-773, 739.
60. Yuen, E.Y. et al. 2012. Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. Neuron 73: 962-977.
61. Duman, R.S. & L.M. Monteggia . 2006. A neurotrophic model for stress-related mood disorders. Biol. Psychiatry 59: 1116-1127.
62. Ota, K.T. et al. 2014. REDD1 is essential for stress-induced synaptic loss and depressive behavior. Nat. Med. 20: 531-535.
63. Chowdhury, G.M. et al. 2012. (1)H-[(1)(3)C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism. Biol. Psychiatry 71: 1022-1025.
64. Homayoun, H. & B. Moghaddam . 2007. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 27: 11496-11500.
65. Neymotin, S.A. et al. 2011. Ketamine disrupts theta modulation of gamma in a computer model of hippocampus. J. Neurosci. 31: 11733-11743.
66. Autry, A.E. et al. 2011. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475: 91-95.
67. Hardingham, G.E. & H. Bading . 2010. Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11: 682-696.
68. Salvadore, G. et al. 2009. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol. Psychiatry 65: 289-295.
69. Salvadore, G. et al. 2010. Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology 35: 1415-1422.
70. Cornwell, B.R. et al. 2012. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol. Psychiatry 72: 555-561.
71. Duncan, W.C. et al. 2013. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int. J. Neuropsychopharmacol. 16: 301-311.
72. Salvadore, G. et al. 2011. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Intl. J. Neuropsychopharmacol. 15: 1063-1072.
73. Valentine, G.W. et al. 2011. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res. 191: 122-127.
74. Machado-Vieira, R. et al. 2009. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J. Clin. Psychiatry 70: 1662-1666.
75. Rybakowski, J.K. et al. 2013. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Human Psychopharmacol. 28: 87-90.
76. Haile, C.N. et al. 2014. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int. J. Neuropsychopharmacol. 17: 331-336.
77. Laje, G. et al. 2012. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol. Psychiatry 72: e27-e28.
78. Krystal, J.H., G. Sanacora & R.S. Duman . 2013. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol. Psychiatry 73: 1133-1141.
79. Abdallah, C.G. et al. 2012. Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting. J. ECT 28: 157-161.
80. Ghasemi, M. et al. 2014. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res. 215: 355-361.
81. Kudoh, A. et al. 2002. Small-dose ketamine improves the postoperative state of depressed patients. Anesthesia Analgesia 95: 114-118, table of contents.
82. Zarate, C. et al. 2012. Replication of ketamine's antidepressant efficacy in bipolar depression: a Randomized Controlled Add-On Trial. Biol. Psychiatry 71: 939-946.
83. Carlson, P.J. et al. 2013. Neural correlates of rapid antidepressant response to ketamine in treatment-resistant unipolar depression: a preliminary positron emission tomography study. Biol. Psychiatry 73: 1213-1221.
84. Ibrahim, L. et al. 2012. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37: 1526-1533.
85. Larkin, G.L. & A.L. Beautrais . 2011. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int. J. Neuropsychopharmacol. 11-5.
86. Mathew, S.J. et al. 2010. Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int. J. Neuropsychopharmacol. 13: 71-82.
87. Okamoto, N. et al. 2010. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. J. ECT 26: 223-227.
88. Phelps, L.E. et al. 2009. Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist. Biol. Psychiatry 65: 181-184.
89. Salvadore, G. et al. 2012. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int. J. Neuropsychopharmacol. 15: 1063-1072.